- Home
- NMRK vs WVE Comparison
NMRK vs WVE Comparison
Compare NMRK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- WVE
- Stock Information
- Founded
- NMRK 1929
- WVE 2012
- Country
- NMRK United States
- WVE Singapore
- Employees
- NMRK N/A
- WVE 268
- Industry
- NMRK Real Estate
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- WVE Health Care
- Exchange
- NMRK Nasdaq
- WVE Nasdaq
- Market Cap
- NMRK 2.4B
- WVE 1.8B
- IPO Year
- NMRK 2017
- WVE 2015
- Fundamental
- Price
- NMRK $14.03
- WVE $11.94
- Analyst Decision
- NMRK Buy
- WVE Strong Buy
- Analyst Count
- NMRK 4
- WVE 10
- Target Price
- NMRK $17.50
- WVE $21.60
- AVG Volume (30 Days)
- NMRK 893.8K
- WVE 872.8K
- Earning Date
- NMRK 02-14-2025
- WVE 03-05-2025
- Dividend Yield
- NMRK 0.87%
- WVE N/A
- EPS Growth
- NMRK 320.81
- WVE N/A
- EPS
- NMRK 0.30
- WVE N/A
- Revenue
- NMRK $2,613,228,000.00
- WVE $53,610,000.00
- Revenue This Year
- NMRK $9.54
- WVE N/A
- Revenue Next Year
- NMRK $13.08
- WVE $48.58
- P/E Ratio
- NMRK $45.81
- WVE N/A
- Revenue Growth
- NMRK 12.15
- WVE N/A
- 52 Week Low
- NMRK $9.44
- WVE $3.50
- 52 Week High
- NMRK $16.10
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- NMRK 54.75
- WVE 44.14
- Support Level
- NMRK $13.61
- WVE $11.10
- Resistance Level
- NMRK $14.41
- WVE $12.35
- Average True Range (ATR)
- NMRK 0.41
- WVE 0.58
- MACD
- NMRK 0.12
- WVE 0.09
- Stochastic Oscillator
- NMRK 70.64
- WVE 50.32
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.